Insider Ledger
CTNM insider buying and SEC filings, explained
Contineum Therapeutics, Inc. · CIK 1855175
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Company profile
- Exchanges
- Nasdaq
- Industry (SIC)
- Pharmaceutical Preparations
- State of incorporation
- DE
- Fiscal year end
- Dec 31
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$1.9M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Sep 8, 2026 | Planned (10b5-1) | Carmine N. Stengone (CEO and Director) sold 2,500 shares at about $16.46 ($41K), marked as a 10b5-1 plan trade. Holdings down 13% to 17,217 shares. | SEC filing Filed Sep 8, 2026 |
| Aug 3, 2026 | Planned (10b5-1) | Carmine N. Stengone (CEO and Director) sold 2,500 shares at about $16.01 ($40K), marked as a 10b5-1 plan trade. Holdings down 13% to 17,217 shares. | SEC filing Filed Aug 3, 2026 |
| Jul 8–9, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 1,040 shares between Jul 8 and Jul 9 at $16.00 ($17K), marked as a 10b5-1 plan trade. Holdings down 1% to 135,202 shares. | SEC filing Filed Jul 10, 2026 |
| Jul 8, 2026 | Planned (10b5-1) | Carmine N. Stengone (CEO and Director) sold 2,500 shares at $16.00 ($40K), marked as a 10b5-1 plan trade. Holdings down 13% to 17,217 shares. | SEC filing Filed Jul 8, 2026 |
| Jun 30–Jul 1, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 37,179 shares between Jun 30 and Jul 1 at about $16.00 ($595K), marked as a 10b5-1 plan trade. Holdings down 22% to 135,202 shares. | SEC filing Filed Jul 2, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Tim Watkins (CMO & Head of Development) sold 10,833 shares at about $16.02 ($174K), marked as a 10b5-1 plan trade. Holdings down 55% to 8,961 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 30, 2026 | Planned (10b5-1) | Carmine N. Stengone (CEO and Director) sold 10,000 shares at about $16.01 ($160K), marked as a 10b5-1 plan trade. Holdings down 37% to 17,217 shares. | SEC filing Filed Jul 1, 2026 |
| Jun 1, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $13.16 ($55K), marked as a 10b5-1 plan trade. Holdings down 3% to 139,372 shares. | SEC filing Filed Jun 1, 2026 |
| May 1, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $13.12 ($55K), marked as a 10b5-1 plan trade. Holdings down 3% to 143,542 shares. | SEC filing Filed May 1, 2026 |
| Apr 6, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $13.43 ($56K), marked as a 10b5-1 plan trade. Holdings down 3% to 147,712 shares. | SEC filing Filed Apr 6, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $15.01 ($63K), marked as a 10b5-1 plan trade. Holdings down 3% to 151,882 shares. | SEC filing Filed Mar 2, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Tim Watkins (CMO & Head of Development) sold 3,611 shares at about $15.02 ($54K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Mar 2, 2026 |
| Feb 24–25, 2026 | Planned (10b5-1) | Carmine N. Stengone (CEO and Director) sold 7,100 shares between Feb 24 and Feb 25 at about $16.02 ($114K), marked as a 10b5-1 plan trade. Holdings down 32% to 14,954 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 24–25, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 8,124 shares between Feb 24 and Feb 25 at about $16.02 ($130K), marked as a 10b5-1 plan trade. Holdings down 5% to 156,052 shares. | SEC filing Filed Feb 26, 2026 |
| Feb 19, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 100 shares at $16.00 ($2K), marked as a 10b5-1 plan trade. Holdings down <1% to 156,052 shares. | SEC filing Filed Feb 20, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Carmine N. Stengone (CEO and Director) sold 400 shares at $16.00 ($6K), marked as a 10b5-1 plan trade. Holdings down 3% to 14,954 shares. | SEC filing Filed Feb 13, 2026 |
| Feb 11, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 400 shares at $16.00 ($6K), marked as a 10b5-1 plan trade. Holdings down <1% to 156,052 shares. | SEC filing Filed Feb 13, 2026 |
| Feb 3, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $14.94 ($62K), marked as a 10b5-1 plan trade. Holdings down 3% to 156,052 shares. | SEC filing Filed Feb 5, 2026 |
| Jan 28, 2026 | Planned (10b5-1) | Tim Watkins (CMO & Head of Development) sold 3,611 shares at about $14.18 ($51K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Jan 30, 2026 |
| Jan 5, 2026 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $10.44 ($44K), marked as a 10b5-1 plan trade. Holdings down 3% to 160,222 shares. | SEC filing Filed Jan 6, 2026 |
| Dec 29, 2025 | Planned (10b5-1) | Tim Watkins (CMO & Head of Development) sold 3,611 shares at about $12.06 ($44K), marked as a 10b5-1 plan trade. Holdings down 100% to 0 shares. | SEC filing Filed Dec 30, 2025 |
| Dec 23, 2025 | Planned (10b5-1) | Daniel S. Lorrain (Chief Scientific Officer) sold 4,170 shares at about $12.23 ($51K), marked as a 10b5-1 plan trade. Holdings down 2% to 164,392 shares. | SEC filing Filed Dec 30, 2025 |
26 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
| Filed | Items | Tag | Source |
|---|---|---|---|
| Nov 3, 2026, 4:08 PM ET 8-K | Earnings released (Item 2.02) | SEC filing |
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow CTNM in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.